Get the Stockscreener App
96.81
1.40%
1.34
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $96.81, with a volume of 17.55M.
It is up +1.40% in the last 24 hours and down -12.56% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$95.47
Open:
$95.62
24h Volume:
17.55M
Relative Volume:
1.46
Market Cap:
$168.22B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
26.97
EPS:
3.5895
Net Cash Flow:
$7.40B
1W Performance:
-3.48%
1M Performance:
-12.56%
6M Performance:
-24.68%
1Y Performance:
-26.09%
1-Day Range:
$94.87
$97.14
1-Week Range:
$93.92
$102.48
52-Week Range:
$93.92
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
96.81 | 165.90B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
343.32 | 129.59B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.19 | 109.96B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.23 | 94.25B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.99 | 45.58B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories $ABT Shares Sold by Lbp Am Sa - MarketBeat
Abbott Laboratories (NYSE:ABT) Short Interest Up 19.4% in March - MarketBeat
Abbott Reaches Preliminary Settlement in Derivative Governance Case - TipRanks
[8-K] ABBOTT LABORATORIES Reports Material Event - Stock Titan
ABT Maintained by Piper Sandler -- Price Target Lowered to $115 - GuruFocus
Abbott Labs Stock (ABT) Hit with Slew of Downgrades After Earnings - TipRanks
China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and Sanofi - GlobeNewswire Inc.
Abbott Laboratories Sales Growth Outlook 'Leaves Room For Upside': Analyst - Benzinga
Abbott stock crash: Rebound could be coming fast - MSN
Piper Sandler cuts Abbott Labs stock price target on weak diabetes sales - Investing.com
Abbott Stock Crash: Rebound Could Be Coming Fast - MarketBeat
TD Cowen lowers Abbott stock price target to $115 on guidance cut - Investing.com
ABT Maintained by Evercore ISI Group -- Price Target Lowered to $120 - GuruFocus
RBC Capital lowers Abbott Labs stock price target on Q1 results - Investing.com Australia
Abbott Labs’ Financial Results Narrowly Beat Forecasts - Baystreet.ca
Bernstein SocGen cuts Abbott Labs stock price target on growth concerns - Investing.com Canada
Citigroup Lowers Abbott Laboratories (NYSE:ABT) Price Target to $108.00 - MarketBeat
Oppenheimer Adjusts Price Target on Abbott Laboratories to $115 From $132, Maintains Outperform Rating - marketscreener.com
Abbott (ABT) Stock Price Prediction 2027: Analyst Targets, Q1 2026 Earnings & Bull/Bear Scenarios - techi.com
Abbott lowers EPS guidance on Exact Sciences buy as shares slide - Fierce Biotech
Citigroup Cuts Price Target on Abbott Laboratories to $108 From $136, Maintains Buy Rating - marketscreener.com
Benchmark Adjusts Price Target on Abbott Laboratories to $120 From $145, Maintains Buy Rating - marketscreener.com
JPMorgan Adjusts Price Target on Abbott Laboratories to $110 From $123, Maintains Overweight Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Abbott Laboratories to $109 From $122, Maintains Overweight Rating - marketscreener.com
Benchmark cuts Abbott Labs stock price target on valuation to $120 - Investing.com
Oppenheimer cuts Abbott stock price target to $115 on guidance - Investing.com
Abbott Laboratories (NYSE:ABT) Q1 2026 Earnings Call Transcript - Insider Monkey
Why Is Abbott Stock Trending Lower? - Trefis
Abbott Price Prediction: Where Will the Stock Be in 2027 - 24/7 Wall St.
Why Abbott Laboratories stock tumbled on Thursday - MSN
Abbott Laboratories Stock Tumbles 6% On Weak Q2 Earnings Guidance - TIKR.com
BofA cuts Abbott Labs stock price target on growth concerns - Investing.com
BofA cuts Abbott Labs stock price target on growth concerns By Investing.com - Investing.com Australia
Mizuho Adjusts Price Target on Abbott Laboratories to $115 From $125, Maintains Neutral Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $134, Maintains Outperform Rating - marketscreener.com
RBC Cuts Price Target on Abbott Laboratories to $130 From $135, Keeps Outperform Rating - marketscreener.com
Dr. Alexander Crider: There is a hidden cost to the Abbott verdict for premature babies - Chicago Tribune
Abbott price target lowered to $120 from $150 at BofA - TipRanks
Abbott Laboratories vs Medtronic: Which Stock Could Rally? - Trefis
Is Medtronic a Better Buy Than Abbott Laboratories? - Trefis
Abbott Laboratories (ABT) Q1 2026 Earnings Call Highlights: Strong Medical Devices Growth Amid ... By GuruFocus - Investing.com Canada
Inside Biotech: Abbott’s solid quarter isn’t enough as $21B bet rattles investors - Proactive financial news
Flu Season Fades, Abbott Stumbles: Is the 54-Year Dividend King Still Worth the Crown? - NAI500
New cancer diagnostics and product updates see Abbott Laboratories stock fall amid oversold technicals - Traders Union
Why Abbott Laboratories Stock Tumbled on Thursday - The Motley Fool
Abbott Laboratories Bets on Devices in 2026 Call - TipRanks
Abbott Laboratories (ABT) Faces Investor Concerns After Earnings Update - GuruFocus
Abbott Laboratories (ABT) Lowers Earnings Outlook Amid Acquisiti - GuruFocus
Abbott Laboratories (ABT) Shares Fall 6.0% -- What GF Score of 8 - GuruFocus
Is Abbott Laboratories (ABT) Now Offering Value After A 20% Share Price Slide? - simplywall.st
Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix - WSJ
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):